Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (Q29618155)

Europe PubMed Central

title

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

author name string

Roberts PJ

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

Der CJ

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

14 May 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

volume

26

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

page(s)

3291-310

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

issue

22

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

Germline mutations in HRAS proto-oncogene cause Costello syndrome

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Isoprenylcysteine carboxyl methyltransferase deficiency in mice

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Mutations of the BRAF gene in human cancer

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

1 May 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

ERBB receptors and cancer: the complexity of targeted inhibitors

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Nuclear factor-kappaB in cancer development and progression

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

How many drug targets are there?

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Germline KRAS mutations cause Noonan syndrome

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

BRAF mutation predicts sensitivity to MEK inhibition

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

The RAF proteins take centre stage

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

The specificities of protein kinase inhibitors: an update

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Protein kinases as drug targets in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Lipid posttranslational modifications. Farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Validating cancer drug targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Emerging role of RAB GTPases in cancer and human disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Farnesyltransferase inhibitors: promises and realities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Ras family signaling: therapeutic targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Point mutations of protein kinases and individualised cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Signaling through the epidermal growth factor receptor during the development of malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

1 reference

7 January 2021

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Small molecule p38 inhibitors: novel structural features and advances from 2002-2005.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Mechanisms of cutaneous toxicities to EGFR inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

RAS oncogenes: the first 30 years.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Targeting JNK for therapeutic benefit: from junk to gold?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Signaling interplay in Ras superfamily function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Lapatinib: current status and future directions in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Using natural product inhibitors to validate Hsp90 as a molecular target in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Targeting signal transduction as a strategy to treat inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

1 reference

7 January 2021

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Contributions of human tumor xenografts to anticancer drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

The epidermal growth factor receptor pathway: a model for targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Raf kinases: oncogenesis and drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Analysis of the transcriptional program induced by Raf in epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Mechanisms of drug inhibition of signalling molecules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Opinion: Searching for the elusive targets of farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Inhibitors of the HSP90 molecular chaperone: current status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

The mighty mouse: genetically engineered mouse models in cancer drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Understanding Ras: 'it ain't over 'til it's over'.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Recent advances in the research and development of RAF kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Recurring HRAS mutation G12S in Dutch patients with Costello syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Trafficking of the ErbB receptors and its influence on signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Post-prenylation-processing enzymes as new targets in oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

A genome-wide survey of RAS transformation targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210422

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210422

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

318778

1013706518

0 references

318778

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17496923

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017